Dr. Mark A. Varney, PhD., will present at the World Orphan Drug Congress to be held on April 22-24, 2015 in Washington DC. In his capacity as Chief Executive Officer of Neurolixis, Dr. Varney will participate in the ‘Pitch and Partner’ session (April 23, 1:30pm). His presentation is entitled “NLX-101 for the treatment of Rett Syndrome”.

NLX-101 is a clinical candidate being developed by Neurolixis as a treatment for Rett syndrome, a serious orphan disorder that affects about 30 000 girls in Europe and North America. NLX-101 exhibits a remarkably promising profile of therapeutic activity in transgenic mouse models of Rett syndrome, reversing the breathing arrhythmia that is seen in Rett syndrome mice and is a serious symptom of the disorder in human. Investigation of the physiological effects of NLX-101 is being conducted with support from the International Rett Syndrome Foundation and the Rett Syndrome Research Trust (see previous press releases).

Neurolixis is actively pursuing opportunities to partner the clinical development of NLX-101 – contact us for further information.

For full details of the World Orphan Drug Congress program see the meeting website.